The empty vector was used to generate CAL-1-EV cells. Lentiviral particles were produced in 293T cells by calcium phosphate transfection. Spin transduction of CAL-1 cells with 8 μg/mL Polybrene was performed at 1800 Gefitinib mw rpm for 90 min. GFP-positive CAL-1 cells were sorted under low-pressure conditions on the

FACSAria. For RNA interference, CAL-1 cells were transfected with 75 nM siRNA directed against NAB2 (siRNA ID: s9248; Ambion/Applied Biosystems) or the Silencer Selected Negative Control siRNA #1; Ambion/Applied Biosystems) together with 25 nM siGLO Transfection Indicator (Dharmacon) with transfection reagent DharmaFECT 4 (Dharmacon) according to the manufacturer’s protocol. Transfection efficiency was determined by flow cytometry (Supporting Information Fig. 3A), and silencing was confirmed at protein levels by western

blot (Supporting Information Fig. 3B). A total of 105 primary human pDCs were stimulated with 12.5 μg/mL CpG A (Invivogen) or left untreated for 4 h or overnight in complete medium in a 96-well plate for RT-PCR and flow cytometry or western blot analysis, respectively. CAL-1 cells (7 × 105) were seeded overnight in a 24-well plate in 2 mL medium. A total of 1.1 mL medium was replaced with 100 μL FBS-free RPMI medium containing 12.5 μg/mL CpG B or Ctrl CpG B, 5 μg/mL Imiquimod (Invivogen), or 100–200 ng/mL IFN-β (PBL Medical Laboratories) to prevent FBS-mediated NAB2 induction selleck compound ([14], data not shown). A total of 50 μM SB203580, 2.5 μM BAY11–7082, 5 μM PI-103 (Tocris Bioscience), 200 mM Rapamycin (Calbiochem) or DMSO alone, or 0.1 μg/mL B18R (eBioscience) were added to cells 30 min prior to CpG stimulation. After stimulation, supernatant was harvested for cytokine analysis and cells were washed once with PBS before further analysis. pDC cell sorting was performed with anti-CD45RA-FITC (BD Biosciences) and anti-CD123-PE (Miltenyi Biotec). Cell surface staining was performed aminophylline with Anti-CD40-PE (Beckman Coulter) or isotype control

IgG1-PE (BD Biosciences), and anti-TRAIL (2E5; Enzo Life Sciences), or control mouse IgG1 (BD Biosciences), followed by anti-mouse IgG1-Biotin (Enzo Life Sciences) and Steptavidin-allophycocyanin (BD Pharmingen). Dead cell exclusion was performed with propidium iodide. Intracellular IRF-7 staining was performed by fixation and permeabilization with Cytofix/cytoperm Solution (BD Biosciences) and PBS containing 0.5% saponin and 2% FCS, followed by staining with IRF-7 (H-246; Santa Cruz Biotechnologies) or isotype control (Imgenex) and anti-rabbit IgG Alexa 568 (Invitrogen). Flow cytometry was performed with FACS Calibur or LSRII (BD Biosciences). Analysis was performed with FlowJo software (Tristar).